Prostate Cancer Prevention Clinic for Men With Risk of Familial Prostate Cancer

Launched by HEINRICH-HEINE UNIVERSITY, DUESSELDORF · Dec 26, 2022

Keywords

ClinConnect Summary

The "ProFam-Risk" clinical trial is designed to help understand and improve the care of men who are at higher risk for developing prostate cancer, especially those with a family history or specific genetic factors. Prostate cancer is common, affecting about 1 in 9 men, but certain individuals, particularly those with family members diagnosed with the disease, may face a significantly higher risk. This study will look at about 100 men each year for three years, focusing on gathering personal health information, imaging results, and genetic data to create tailored recommendations for monitoring and managing their health.

To join this trial, participants should be healthy men aged 18 or older who have a family history of prostate cancer—like having two close relatives diagnosed at any age or one diagnosed before age 60—or those with specific genetic mutations related to prostate cancer risk. Participants will undergo regular check-ups and possibly some tests, including imaging of the prostate and genetic testing. This research aims not only to detect any cancer early but also to avoid unnecessary treatments for those at lower risk.

Gender

MALE

Eligibility criteria

• Inclusion criteria:
• • Healthy men with familial risk ( ≥ 2 first-degree relatives with PCA diagnosed at any age oder ≥ 1 first-degree relative with PCA diagnosed at the age \<60)
• • healthy men with genetic risk (BRCA1/2 Germline mutation)
• • Men with PCA and genetic oder familial risk (familial risk = ≥ 2 first-degree relatives with PCA diagnosed at any age oder ≥ 1 first-degree relative with PCA diagnosed at the age \<60; genetic risk= BRCA1/2 Germline mutation)
• Exclusion criteria:
• • \<18 years
• • no consent